It's exciting to see progress on ACR16, a new drug being developed by Carlsson Research, but it will be years before this drug is approved for use by HD patients. Dr. Nathan Goodman discusses ways to speed up the endgame and get promising drugs to Huntington's people more quickly.

Carlsson Research is a small biotech company that is developing a promising drug for Huntington's, called ACR16. Dr. LaVonne Veatch Goodman tells the history of this drug and her hopes for more good news to come next.

It is indeed an opportune time for Prestwick to have a company leader who is described as having "experience in managing regulatory processes" by Prestwick's board of directors. Hopefully, he will be successful in gaining FDA approval for tetrabenazine. Read the press release on the company's website.

The U.S. Food and Drug Administration (FDA) will soon be deciding whether to approve tetrabenazine. Drs. LaVonne Veatch Goodman and Nathan Goodman put the tetrabenazine story into the broader context of providing rapid access to drugs for people with serious illnesses like Huntington's.

The Hereditary Disease Foundation, led by Dr. Nancy Wexler, is collecting letters from Huntington's people that will be forwarded to the FDA. See the announcement on the HDF website.

There is little doubt that tetrabenazine improves chorea in many patients, and there is strong evidence that the side effects can usually be controlled. Dr. LaVonne Veatch Goodman argues that Huntington's patients and their doctors should have the right to decide whether to use this drug.

In a report reviewing over two decades of clinical experience with tetrabenazine and depression, doctors from Baylor College of Medicine report promising results in the journal Clinical Neuropharmacology. Dr. LaVonne Veatch Goodman summarizes the findings and explains why this is important for Huntington’s people.

Clinical trials are starting for a new Huntington's drug called Dimebon. This news report by Linda Miller and Dr. LaVonne Veatch Goodman provides background on the drug and information on the trial including where to sign up.

Researchers from the University of Iowa School of Medicine report on the frequency of severe depression across the stages of Huntington’s disease. Dr. LaVonne Veatch Goodman summarizes the findings and stresses the need for treatment of this serious component of HD with drugs that are available now.

In two separate reports, researchers from the University of Indiana and Imperial College in England report promising results on a potential new biomarker for Huntington's. With more work, this could lead to shorter clinical trials for HD drugs. Summary by Dr. LaVonne Veatch Goodman.